Cargando…
Low-molecular-weight heparins in the treatment of venous thromboembolism
Venous thromboembolism is a common disease that is associated with considerable morbidity if left untreated. Recently, low-molecular-weight heparins (LMWHs) have been evaluated for use in acute treatment of deep venous thrombosis and pulmonary embolism. Randomized studies have shown that LMWHs are a...
Autores principales: | Ageno , Walter, Huisman, Menno V |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59610/ https://www.ncbi.nlm.nih.gov/pubmed/11714421 http://dx.doi.org/10.1186/cvm-1-2-102 |
Ejemplares similares
-
Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001) -
Higher Adherence to Treatment With Low-Molecular-Weight-Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancer-Associated Venous Thromboembolism
por: van der Wall, Sake J., et al.
Publicado: (2018) -
Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007) -
Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008) -
Recent advances in the management of venous thromboembolism
por: Ageno, Walter
Publicado: (2010)